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Abstract
Background: Cimetidine, a histamine type-2 receptor antagonist, has been reported to inhibit the
growth of glandular tumors such as colorectal cancer, however the mechanism of action underlying
this effect is unknown. Adenoid cystic carcinoma is well known as a malignant salivary gland tumor
which preferentially invades neural tissues. We demonstrated previously that human salivary gland
tumor (HSG) cells spontaneously express neural cell adhesion molecule (NCAM), that HSG cell
proliferation may be controlled via a homophilic (NCAM-NCAM) binding mechanism and that
NCAM may be associated with perineural invasion by malignant salivary gland tumors. We further
demonstrated that cimetidine inhibited NCAM expression and induced apoptosis in HSG cells.
Here, we investigated the effects of cimetidine on growth and perineural/neural invasion of salivary
gland tumor cells.
Methods: In this study, we have examined the effect of cimetidine on cancer cell adhesion to
neural cells in vitro, one of the critical steps of cancer invasion and metastasis. We have also used
an in vivo carcinogenesis model to confirm the effect of cimetidine.
Results: We have demonstrated for the first time that cimetidine can block the adhesion of HSG
cells to neural cell monolayers and that it can also induce significant apoptosis in the tumor mass
in a nude mouse model. We also demonstrated that these apoptotic effects of cimetidine might
occur through down-regulation of the cell surface expression of NCAM on HSG cells. Cimetidine-
mediated down-regulation of NCAM involved suppression of the nuclear translocation of NF-κB,
a transcriptional activator of NCAM gene expression.
Conclusion: These findings suggest that growth and perineural/neural invasion of salivary gland
tumors can be blocked by administration of cimetidine via induction of apoptosis and in which
NCAM plays a role.
Background
Cimetidine, the first histamine type-2 receptor (H2R)
antagonist to be used clinically, is commonly prescribed
to treat gastro-esophageal reflux disease as well as gastric
and duodenal ulcers [1]. It has been reported that cimeti-
dine improves the survival of patients with malignant
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tumors [2,3], including gastric [4] and colorectal carcino-
mas [5]. Cimetidine has been shown to inhibit growth of
gastrointestinal cancers via several mechanisms including
enhancement of immune activity and inhibition of cancer
cell proliferation [3]. Therefore cimetidine may act by
enhancing the host immune response against tumor cells
[6,7] or by blocking the cell growth-promoting activity of
histamine [5,8-10]. Kobayashi et al. [11] reported that
cimetidine inhibits colon adenocarcinoma cell adhesion
to vascular endothelial cells and prevents metastasis by
blocking E-selectin expression. We also demonstrated
recently that cimetidine inhibited neural cell adhesion
molecule (NCAM) expression and induced apoptosis in
salivary gland tumor cells [12]. However, the exact mech-
anisms by which cimetidine suppresses the development
of salivary gland tumors remain to be elucidated. Adenoid
cystic carcinoma (ACC) is a well known and typical malig-
nant salivary gland tumor. Facial paralysis due to
perineural/neural invasion occurs so frequently that it is
generally accepted as a hallmark of ACCs [13-15], and
inhibition of perineural/neural invasion could be a strat-
egy for arresting the development of ACC.
In this study, we have examined the effect of cimetidine
on cancer cell adhesion to neural cells in vitro, one of the
critical steps of cancer invasion and metastasis. We have
also used an in vivo carcinogenesis model to confirm the
effect of cimetidine. We demonstrated previously [16]
that NCAM is spontaneously expressed in the human sal-
ivary gland tumor HSG cell line, derived from the sub-
mandibular salivary gland, and that HSG cell
proliferation may be controlled via a homophilic (NCAM-
NCAM) binding mechanism. We have also shown that
NCAM may be involved in perineural/neural invasion by
malignant salivary gland tumors [17]. Furthermore, it has
been reported that NCAM expression is regulated by tran-
scription factor κB (NF-κB) and that NF-κB activity is
induced by homophilic NCAM binding [18,19]. NF-κB
has key roles in inflammation, immune response, tumor-
igenesis and protection against apoptosis [20-22]. In most
cell types, NF-κB remains bound to IκBα protein, and
thereby inactive, in the cytoplasm [23,24]. After stimula-
tion by various reagents, IκBα is rapidly phosphorylated
by the IκB kinase (IKK) complex and degraded by the pro-
teasome, allowing NF-κB to translocate to the nucleus and
activate its target gene [21,25,26]. Here we found that
cimetidine blocks not only salivary gland tumor cell adhe-
sion to neural cells, but also tumor growth by inhibiting
the NF-κB-mediated induction of NCAM. We also demon-
strated that cimetidine can induce apoptosis in the inocu-
lated tumor mass in a nude mouse model in which the
salivary gland tumor cell line HSG was injected subcuta-
neously.
Methods
Reagents
For immunoblot analysis of NF-κB, MAb NF-κB p65/RelA
(p65) antibody (Santa Cruz Biotechnology, CA, USA) was
used as a primary antibody. Mouse anti-human NCAM
monoclonal antibody (MAb NCAM antibody; CD56) was
also purchased from Santa Cruz Biotechnology. MAb
ICAM-1 was purchased from Medical & Biological Labora-
tories (Nagoya, Japan). Cimetidine was purchased from
Sigma Chemical Co (MI, USA). H2R blockers were dis-
solved in PBS. Recombinant human TNF-α (R & D Sys-
tems, Inc., Minneapolis, MN) was used for the
stimulation of HSG cells. MTT [3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl tetrazolium bromide] were obtained
from Sigma.
Cell culture
The HSG cell line, derived from a human submandibular
salivary gland, was established by Shirasuna et al. [27]
This cell line was maintained in RPMI 1640 medium sup-
plemented with 10% heat-inactivated fetal bovine serum
(FBS), 100 IU/mL penicillin and 100 mg/mL streptomy-
cin and grown to confluency in 25 cm2 culture flasks at
37°C in a humidified 5% CO2 incubator until required.
Normal human neural progenitor (NHNP) cells and neu-
ral progenitor cell maintenance medium (NPMM) were
purchased from Sanko Junyaku Co., Ltd. (Tokyo, Japan).
NHNP cells were maintained with supplemented NPMM
on 10 cm2 polyethyleneimine (PEI) coated glass plates
until they differentiated to neural cells.
Co-culture of neural cells and HSG cells, and 
morphological observation of apoptotic cells
HSG cells (1 × 105 cells/ml) were added onto a semicon-
fluent monolayer culture of neural cells, incubated for 20
min at 37°C with rotation at 120 rpm, and washed exten-
sively to exclude nonspecific cell attachment. The number
of attached cells was counted directly under a microscope
as reported previously [16]. The cells were then co-cul-
tured for 24 h, after which they were further co-incubated
with various concentrations of cimetidine (10-8 to 10-4 M)
for 24 h. The co-cultured cells were washed extensively to
exclude nonspecific cell attachment. The numbers of
attached cells, and the morphological changes of each cell
type, were observed directly under a confocal laser micro-
scope. For antibody-mediated blocking of cell adhesion,
the neural cells were incubated with antibody to either
NCAM or ICAM-1 (final dilution of 1:200 for both anti-
bodies) for 3 h at 37°C in humidified CO2 incubator, and
then HSG cells were added.
RNA extraction and real-time quantitative RT-PCR
Total RNA was extracted from monolayer HSG cells (1 ×
106 cells/ml) treated with TNF-α (10 ng/ml) or various
concentrations of cimetidine (10-8 to 10-4 M) by the acid-BMC Cancer 2008, 8:376 http://www.biomedcentral.com/1471-2407/8/376
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guanidinium-phenol-chloroform (AGPC) method
reported previously [17]. To confirm the expression pat-
terns of up-regulated or down-regulated NCAM and NF-
κB genes after TNF-α or cimetidine treatment, real-time
quantitative RT-PCR analyses were performed using a Bio-
Rad iCycler system (Bio-Rad, Tokyo, Japan) and an iScript
One-Step RT-PCR kit with SYBR Green I (Bio-Rad) accord-
ing to the manufacturer's instructions. Briefly, the mRNAs
were reverse-transcribed into cDNAs at 50°C for 10 min
and reverse transcriptase was inactivated at 95°C for 5
min. PCR cycling and detection were followed by running
for 45 cycles at 95°C for 10 s and 56°C for 30 s. PCR prim-
ers were designed and synthesized by Sigma-Aldrich, Inc.
(Ishikari, Japan) with consideration of the special design
criteria for real-time PCR primers. The following primer
sequences were used in the PCR reactions: NCAM for-
ward, GAA TGC CAC CGC CAA CCT C; NCAM reverse,
GTC TTC CTC TTG CTC TAT CTG TTC C; NF-κB forward,
AGG CGA GAG GAG CAC AGA TAC; NF-κB reverse, CGG
CAG TCC TTT CCT ACA AGC; GAPDH forward, CAG CCT
CAA GAT CAT CAG CA; GAPDH reverse, ACA GTC TTC
TGG GTG GCA GT. Each sample was amplified in tripli-
cate and the corresponding no-RT mRNA sample was
included as a negative control. The relative mRNA level of
each sample for each gene was normalized to the mRNA
level of GAPDH, a housekeeping gene. The results were
analyzed with the Bio-Rad iCycler Software 3.0 and
Microsoft Excel 97 and presented as fold induction com-
pared with the quantity of GAPDH mRNA (set at 1). The
specificities of PCR products were analyzed by melting
curve data and agarose gel electrophoresis to determine
product size and to confirm that no by-products were
formed.
Protein extraction
To examine RelA translocation to the nucleus, we used a
subcellular proteome extraction kit (S-PEK; Calbiochem,
Darmstadt, Germany) according to the manufacturer's
instructions to extract cytoplasm, cell membrane and
nucleus fractions of HSG cells. Cells were treated with 10
ng/ml of TNF-α and/or 10-4 M cimetidine, pelleted (5 ×
106 cells), washed twice, resuspended in 1 ml of ice-cold
Extraction I containing 5 μl of protease inhibitor mixture,
and then incubated for 10 min at 4°C with gentle agita-
tion. The suspension was centrifuged at 1000 × g at 4°C
for 10 min. The supernatant was used as the cytoplasm
fraction; the pellet was resuspended in 1 ml of ice-cold
Extraction II containing 5 μl of protease inhibitor mixture
and incubated for 30 min at 4°C. It was then centrifuged
at 6000 × g at 4°C for 10 min, and the supernatant was
used as the cell membrane fraction; the pellet was resus-
pended in 500 μl of ice-cold Extraction III containing 5 μl
of protease inhibitor mixture and 1.5 μl of Benzonase®
and incubated for 10 min at 4°C with gentle agitation. It
was then centrifuged at 7000 × g at 4°C for 10 min, and
the supernatant was used as the nucleus fraction. Each
sample was subjected to immunoblot analysis.
Immunoblot analysis
For the detection of RelA protein by gel electrophoresis,
10 μg protein samples were mixed with an equal volume
of SDS-PAGE sample buffer and boiled for 5 min. Each
sample was loaded into a single lane and separated on a
polyacrylamide gel of appropriate percentage. The pro-
teins were then electroblotted onto nitrocellulose mem-
branes. Subsequent immunoblot analysis was carried out
according to the method reported previously [17]. Filters
were scanned and computer-generated images were ana-
lyzed with the National Institutes of Health IMAGE pro-
gram to obtain densitometric values. For each series of
samples (cytoplasm, cell membrane and nucleus), the rel-
ative density of each image was calculated and expressed
as a percentage of the value (arbitrarily set at 100) indi-
cated by an asterisk.
Transfection of HSG cells with plasmids and luciferase 
reporter assay
HSG cells (1 × 105 cells/ml) were cultured for 12 h in 24-
well culture plates containing RPMI1640 supplemented
with 10% FBS. pTKκB2luc, a thymidine kinase (TK) luci-
ferase construct containing five copies of the κB motif
from the CXCL10/IP-10 gene, was kindly provided by
Professor Y. Ohmori [28]. Cells were transiently trans-
fected with pTKκB2luc and pRL-TK reference Renilla luci-
ferase plasmids (Promega, Madison, WI, USA) using
FuGene transfection reagents (Roche, Nutley, NJ, USA),
according to the manufacturer's instructions. At 24 h after
transfection, the cells were treated with TNF-α for various
periods (0, 1, 4, 8 and 24 h). Firefly and Renilla luciferase
activities were assayed using reagents provided by
Promega, according to the manufacturer's instructions.
For standardization of transfection efficiencies, the luci-
ferase activity from pTKκB2luc was normalized to the
Renilla  luciferase activity. The pGL3 control luciferase
plasmid was purchased from Promega.
RNA-mediated interference
Small interfering RNAs (siRNAs) specific for human
NCAM, NF-κB and scrambled (control) were synthesized
by Sigma-Aldrich, Inc. (Ishikari, Japan). The sense and
antisense strand sequences of the oligonucleotides were as
follows: NCAM siRNA sense, GCA AUA UCA AGA UCU
ACA ATT; antisense, UUG UAG AUC UUG AUA UUG
CTT; control siRNA sense, AAU CAC AAU UGC GCA AUA
ATT; antisense, UUA UUG CGC AAU UGU GAU UTT; NF-
κB siRNA sense, GGG UAU AGC UUC CCA CAC UTT;
antisense, AGU GUG GGA AGC UAU ACC CTT; control
siRNA sense, AGU ACU CUC GUA CGC UCG ATT; anti-
sense, UCA UGA GAG CAU GCG AGC UTT. Before trans-
fection, FuGene 6 transfection reagent was mixed withBMC Cancer 2008, 8:376 http://www.biomedcentral.com/1471-2407/8/376
Page 4 of 13
(page number not for citation purposes)
100 nM NCAM, 100 nM NF-κB or 100 nM control siRNA
(3:3.4 μl) in serum-free medium, to a total volume of 500
μl and incubated for 30 min at room temperature. For NF-
κB knockdown, HSG cells (1 × 105 cells/ml) were rinsed
with serum-free medium and transfected in 24-well plates
with either a NF-κB siRNA duplex or a control siRNA,
using FuGene 6 transfection reagents for 48 h at 37°C.
Cells were treated with TNF-α for various periods (0–24
h) and subjected to a Real-Time Quantitative RT-PCR. For
NCAM knockdown, HSG cells (1 × 105 cells/ml) were
rinsed with serum-free medium and transfected in 24-well
plates with an NF-κB-dependent luciferase reporter plas-
mid and either a NCAM siRNA duplex or a control siRNA
for 48 h at 37°C. Cells were treated with TNF-α for 4 h and
subjected to a luciferase reporter assay and immunoblot
analysis.
Nude mouse model of HSG tumor mass
All of the experimental procedures were performed with
the approval of the Animal Experimentation Committee
of the Meikai University School of Dentistry. Specific
pathogen-free athymic BALB/c female mice, 3–4 weeks of
age, were kept under sterile conditions in a laminar flow
room in cages with filter bonnets and fed a sterilized
mouse diet and water. The mice were anesthetized by
inhalation of diethyl ether. HSG cells (1 × 106 cells) in 100
μl of PBS were injected subcutaneously into the back of
each mouse with a 27-gauge needle. Tumor size was meas-
ured daily with calipers, and the HSG tumor masses in all
mice, movable and elastic-hard, grew to approximately 10
mm in diameter by three weeks after HSG cell inocula-
tion. To examine the effects of H2R antagonists, the mice
were treated with 10-4 or 10-2 M/day cimetidine or saline
(control) by intratumoral injection for seven consecutive
days after the HSG tumor mass had reached approxi-
mately 10 mm in diameter. Subsequently, cimetidine or
saline (control) was administered every other day for an
additional 5 weeks (a total of 9 weeks after HSG cell
implantation).
Quantification and apoptosis detection of tumor mass in 
nude mice
At nine weeks after HSG cell injection, the animals were
sacrificed and the status of the tumor mass was evaluated
quantitatively (Table 1). The tumor volume (V, mm3) was
calculated as 0.5 × L × W2, where L = length (mm) and W
= width (mm), respectively. The percentage of tumor
growth inhibition was expressed as the mean (± SD)
tumor volumes (calculated in each group of ten mice) rel-
ative to the volume of tumors injected with control saline.
The back skin was excised and cut into 2–3-mm thick
slices. Then, a formalin-fixed, paraffin-embedded speci-
men was obtained for subsequent H&E staining and
apoptosis analysis. Terminal deoxynucleotidyl transferase
(TDT) dUTP nick end labelling (TUNEL) method was per-
formed for evaluation of apoptotic cells using an in situ
apoptosis detection kit (Takara, Shiga, Japan). Briefly, the
deparaffinized sections were treated with 20 μg/ml protei-
nase K for 15 min and immersed in absolute methanol
containing 0.3% H2O2 for 10 min at room temperature to
block endogenous peroxidase activity. After washing in
PBS, sections were incubated with TDT enzyme in a
humidified chamber at 37°C for 1 h. After washing with
PBS, the slides were incubated with diluted streptavidin-
peroxidase (1:1000) for 30 min at room temperature. Pos-
itive cells were visualized using a diaminobenzidine sub-
strate and counterstained with hematoxylin. TUNEL
positive cells showed dark gray staining of the nucleus
suggestive of internucleosomal DNA cleavage.
Statistical analysis
The correlations between the results of experimental treat-
ments were evaluated by the two-tailed Student's t test.
Differences in probability values (p-values) of less than
0.05 were considered statistically significant in all analy-
ses. All analyses were performed with StatView statistical
software (version 5.0; SAS Institute Inc., Cary, NC).
Ethical considerations
The study was approved by the Research Ethics Commit-
tee of the Meikai University School of Dentistry, Saitama,
Japan (reference number: A0801).
Results
Suppression of tumor cell adhesion to neural cells by 
cimetidine
To examine the effects of cimetidine on HSG cell adhesion
to neural cells, a monolayer cell adhesion assay was car-
Table 1: Effect of cimetidine at 9 weeks after subcutaneous inoculation of HSG cells in nude mice
Control (saline) Cimetidine (M/day)
10-4 10-2
Injected 1 × 106 cells 9/10 (90%) 4/10 (40%)a 0/10 (0%)b
Mean Tumor Volume, mm3 ± SD (% control) 600.9 ± 12.97 (100%) 58.35 ± 2.67 (9.71%)a 0 (0%)b
A mouse in the control group (1/10) died unexpectedly. Tumor volume was calculated as width2 × length × 0.5.
a P < 0.05 (compared with control).
b P < 0.001.BMC Cancer 2008, 8:376 http://www.biomedcentral.com/1471-2407/8/376
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ried out. As shown in Fig. 1A, HSG cells adhered strongly
to neural cells. Using this model, we investigated the
effects of various H2R antagonists at a range of non-cyto-
toxic concentrations (from 10-8 to 10-4 M [8,9]; also con-
firmed by MTT assay in a previous study [12]). Cultured
neural cells were pretreated with cimetidine or other H2R
antagonists for 24 h before the addition of HSG cells. After
HSG cells were added, the cell adhesion assay was per-
formed. As shown in Fig. 1A, adhesion of HSG cells to
neural cells was inhibited by cimetidine in a dose-depend-
ent manner. However, the other H2R antagonists, famoti-
dine and ranitidine, had no inhibitory effect (data not
shown). Aithough HSG cells and neural cells were further
co-incubated with various concentrations of cimetidine
(10-8 to 10-4 M) for 24 h, morphological change to apop-
totic cells was not observed in neural cells. However, HSG
cells obviously underwent apoptosis. This finding has
shown in a previous study [12]. To confirm that HSG
adhesion to neural cells was a result of a cognate interac-
tion between NCAM (on HSG) and NCAM (on neural
cells), specific antibodies were added to block these mol-
ecules before the monolayer cell adhesion assay. Preincu-
bation of HSG cells with an MAb NCAM abolished their
ability to adhere to neural cells (Fig. 1B). Similarly, when
neural cells were preincubated with the MAb NCAM, HSG
adhesion to neural cells was also blocked (Fig. 1B). In
contrast, pre-incubation of HSG cells with anti-ICAM-1
antibody did not significantly reduce cell adhesion (Fig.
1B,  photo and graph). These findings indicate that
homophilic NCAM binding is the primary mediator of
cell adhesion between HSG cells and neural cells in this
assay system.
Effects of cimetidine on NCAM and NF-κB gene expression
To investigate the effect of cimetidine on NCAM and NF-
κB mRNA levels, real-time quantitative RT-PCR analysis
was carried out. Total RNA purified from HSG cultures
treated with various concentrations of cimetidine at non-
cytotoxic concentrations (from 10-8 to 10-4 M) was quan-
titated by real-time RT-PCR using specifically designed
primer pairs. Surprisingly, the relative quantities of both
NCAM and NF-κB mRNA rapidly decreased after treat-
ment with 10-8 M cimetidine for 24 h, and then continued
to decrease further at higher doses of cimetidine (Fig. 2A).
As a second step, we performed a time-course analysis on
NCAM and NF-κB mRNA expression in HSG cells treated
with 10-4 M cimetidine (Fig. 2B). The relative quantity of
NCAM mRNA rapidly decreased in the first 15 min, and
then gradually decreased in a time-dependent manner.
However, the relative quantity of NF-κB mRNA showed
almost no variation up to 8 h, but had decreased after 24
h. Thus, while the rate of induction of NCAM mRNA
declined rapidly, induction of NF-κB mRNA only
declined slowly. These findings indicate that cimetidine
time- and dose-dependently down-regulates the expres-
sion of NCAM mRNA and also reduces NF-κB mRNA
expression in HSG cells in a dose-dependent fashion. As a
control experiment, we performed a time-course analysis
of NCAM and NF-κB mRNA expression in HSG cells
treated with 10 ng/ml of TNF-α (Fig. 2C). At first, the rel-
ative quantity of NF-κB mRNA was constitutively induced
in HSG cells and was gradually increased upon stimula-
tion with TNF-α, an effect that reached a peak at 60 min
and then time-dependently decreased up to 24 h. With an
increasing quantity of NF-κB mRNA, the relative quantity
of NCAM mRNA was gradually increased upon stimula-
tion with TNF-α up to 24 h in a time-dependent manner.
These results strongly suggest that NCAM mRNA is
induced by the activation of NF-κB and may play a critical
role in proliferative activity of HSG cells. To confirm
whether NF-κB activation indeed increased NCAM mRNA
in HSG cells, we performed a siRNA approach to reduce
the expression of NF-κB and determined the effects on the
basal and TNF-α-induced activity of NF-κB. As shown in
Fig 2D, NF-κB knockdown by NF-κB siRNA greatly
reduced NCAM mRNA expression in HSG cells, in com-
parison with transfection using NF-κB scrambled siRNA.
These data indicate that NCAM mRNA is indeed induced
by the activation of NF-κB in HSG cells.
Cimetidine inhibits TNF-α-mediated NF-κB activation in 
HSG cells
To examine how RelA expression is regulated in HSG cells
upon stimulation with TNF-α, immunoblot analysis was
carried out followed by densitometric analysis. RelA pro-
tein was localized in the cytoplasm of HSG cells and was
transported to the nucleus upon stimulation with TNF-α,
an effect that reached a peak at 30 min and then decreased
at 60 min (Fig. 3A). When the time course of RelA protein
expression was analyzed up to 24 h, nuclear translocation
of RelA was further decreased (data not shown). Regula-
tion of RelA expression in HSG cells after stimulation with
cimetidine was also analyzed. RelA was primarily local-
ized in the cytoplasm with small quantities also detected
in the cell membrane. The intensity of RelA expression in
HSG cell membranes was decreased in a time-dependent
manner by treatment with 10-4 M cimetidine up to 60
min, whereas the intensity of RelA expression in cyto-
plasm of HSG cells gradually increased up to the same
period (Fig. 3B). Interestingly, although the quantity of
NCAM mRNA was time-dependently down-regulated in
HSG cells treated with 10-4 M cimetidine, real-time quan-
titative RT-PCR showed that the relative amount of NF-κB
mRNA was not markedly down-regulated early after treat-
ment (Fig. 2B). Taken together, these results show that
cimetidine treatment of HSG cells resulted in complete
inhibition of nuclear translocation of NF-κB, even though
the relative quantity of NF-κB mRNA is sufficiently
observed. Thus down-regulation of NCAM is induced via
suppression of NF-κB activity by cimetidine. This effectBMC Cancer 2008, 8:376 http://www.biomedcentral.com/1471-2407/8/376
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Figure 1 (see legend on next page)BMC Cancer 2008, 8:376 http://www.biomedcentral.com/1471-2407/8/376
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may play a critical role in cimetidine-induced apoptosis of
HSG cells.
We also examined the effect of cimetidine on TNF-α-
induced nuclear translocation of RelA. RelA transport to
the nucleus was detectable in HSG cells stimulated with
10 ng/ml of TNF-α and 10-4 M cimetidine for 30 min (Fig.
3C). However, transport was markedly inhibited when
compared with treatment with TNF-α alone. In contrast,
the other H2R antagonists failed to block the nuclear
translocation of RelA induced by TNF-α (data not shown).
To investigate the effect of TNF-α on NF-κB-dependent
transcriptional activity in HSG cells, a luciferase reporter
assay was performed. TNF-α caused strong induction of
luciferase activity (Fig. 3D, left). Maximum NF-κB-
dependent transcription was observed at 4 h, with a 5-fold
increase in luciferase activity compared with cells not
exposed to TNF-α, and no further increase with time was
observed. However, constitutive NF-κB activity was not
observed in HSG cells. The increase in luciferase activity
was completely dependent on the presence of κB sites,
since the control plasmid lacking the κB elements did not
respond to TNF-α (Fig. 3D, right). Furthermore, luciferase
activities in HSG cells were time-dependently decreased in
response to 10-4 M cimetidine from 4 h after cimetidine
stimulation (Fig. 3D, left). Half-maximal inhibition of
luciferase activity was detected at 24 h after stimulation
with 10-4 M cimetidine.
To test whether cimetidine can suppress induction of luci-
ferase activity after TNF-α stimulation, a luciferase
reporter assay was also carried out. Induction of luciferase
activity by TNF-α was inhibited by cimetidine in a time-
dependent fashion (Fig. 3D, left). The decrease in luci-
ferase activity was completely dependent on the presence
of κB sites, since the control plasmid lacking the κB ele-
ments did not respond to cimetidine (Fig. 3D, right).
Together, these data indicate that cimetidine has a specific
and potent inhibitory effect on NF-κB-dependent transac-
tivation.
NCAM is a regulator for NF-κB activation in HSG cells
To determine whether endogenous NCAM indeed func-
tions as a regulator for NF-κB activation by TNF-α in HSG
cells, we used a siRNA approach to reduce the expression
of NCAM and determined the effects on the basal and
TNF-α-induced activity of NF-κB. As expected, the NCAM
protein was markedly reduced by NCAM siRNA (Fig. 4A).
We then assessed the effect of NCAM siRNA on NF-κB-
dependent transcriptional activity by TNF-α for 4 h. As
shown in Fig 4B, NCAM knockdown by NCAM siRNA
greatly reduced NF-κB activation by TNF-α in HSG cells,
in comparison with transfection using NCAM scrambled
siRNA. However, NCAM siRNA had no effect on constitu-
tive NF-κB activity in HSG cells. These data indicate that
NCAM functions as a regulator for NF-κB activation
induced by TNF-α in HSG cells.
Suppression of tumor growth and induction of apoptosis in 
the tumor mass in nude mice by cimetidine
We then examined the effects of cimetidine on tumor
development in vivo in a nude mouse model. Mice were
inoculated with HSG (1 × 106 cells) subcutaneously (Fig.
5A), and the effects of cimetidine on the extent of the HSG
tumor mass were evaluated. Nine weeks after the injection
of HSG cells, mice were sacrificed and the status of the
tumor mass was examined histopathologically. As dem-
onstrated in Table 1, cimetidine not only prevented the
growth of the HSG tumor mass, but also induced a dose-
dependent reduction in tumor volume. One mouse in the
control group (1/10) died unexpectedly. As shown in Fig.
5B, histopathological findings revealed that the tumor
mass was composed of several nodular tumors. The small
nodes were composed of large round tumor cell cords
clearly demarcated from the stroma. Inflammatory small
round cell infiltration was found in the stroma. At 10-4 M
cimetidine, HSG tumor mass in 6 of 10 mice (60%) was
resolved. Although remaining tumor cells were identified
in 4 of 10 mice (40%) in which an HSG tumor mass had
formed, there was clear regression of HSG tumor mass
(Table 1) with evidence of extensive apoptotic cell death
as observed by TUNEL in HSG tumors treated with 10-4 M
Inhibition of HSG tumor cell adhesion to neural cells Figure 1 (see previous page)
Inhibition of HSG tumor cell adhesion to neural cells. A, various concentrations of cimetidine were added, and the 
interaction of HSG cells with neural cells was examined. Phase-contrast microscopic pictures of representative experiments 
are shown. The number of HSG cells adhering to the neural cell monolayer was counted and is shown in the bar graph. B, 
NCAM antibody was added and the interaction of HSG cells with neural cells was examined. Phase-contrast microscopic pic-
tures of representative experiments are shown. The number of HSG cells adhering to the neural cell monolayer was counted 
and is shown in the bar graph. The label 'HSG (treated with MAb NCAM)-neural cell interaction' and the black column in the 
graph indicate the number of HSG cells adhering to the neural cells when the HSG cells were preincubated with the MAb 
NCAM. The label 'HSG-neural cell (treated with MAb NCAM) interaction' and the gray column in the graph indicate the 
number of HSG cells adhering to the neural cells when the neural cells were preincubated with the MAb NCAM. ICAM-1 anti-
body was also added, and the results are shown as a label 'HSG (treated with MAb ICAM-1)-neural cell interaction' and in the 
diagonally shaded column (n = 3 experiments; means ± SD).BMC Cancer 2008, 8:376 http://www.biomedcentral.com/1471-2407/8/376
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cimetidine (Fig. 5C). The significant morphologic
changes, including shrinkage of cytoplasm, fragmented
nuclei and release of apoptotic vesicles in HSG tumor
mass, were also observed by the microscopic analysis (Fig.
5C, right). At the highest dose of cimetidine (daily doses
of 10-2 M), the HSG tumor mass was completely resolved
when 1 × 106 HSG cells were injected subcutaneously
(none of the ten mice had detectable tumor mass; Table 1
and Fig. 5D). Famotidine or ranitidine at doses equivalent
to that of cimetidine had no inhibitory effect on the
growth of the HSG tumor mass (data not shown). In a
repeat experiment using a greater number of HSG cells (1
× 107) for inoculation, cimetidine demonstrated similar
effects on the prevention of tumor growth (data not
shown). Finally, immunohistochemical examination
revealed that the expression of NCAM in HSG tumor mass
was decreased by cimetidine in a dose-dependent fashion
(Fig. 5E). These findings indicate that cimetidine effec-
tively reduces the expression of NCAM, and ultimately
induces apoptosis to HSG tumor masses in nude mice.
Discussion
Cimetidine, the most studied H2R antagonist, has been
shown to possess anti-tumor activity against colon, gastric
and kidney cancers, and melanomas [5,8-10]. A recent
study suggested that this action of cimetidine may be
Effects of cimetidine on NCAM and NF-κB gene expression Figure 2
Effects of cimetidine on NCAM and NF-κB gene expression. A, the relative quantities of both NCAM and NF-κB 
mRNA were suddenly decreased by treatment with 10-8 M cimetidine for 24 h, and then kept decreasing slightly by treatment 
with the higher doses of it. B, the relative quantity of NCAM mRNA was rapidly decreased in the first 15 min, and then contin-
ued to decrease in a time-dependent manner up to 24 h. However, the relative quantity of NF-κB mRNA showed almost no 
variation up to 8 h, and after that decreased at 24 h. C, initially, the relative quantity of NF-κB mRNA was constitutively 
induced in HSG cells and was gradually increased upon stimulation with TNF-α, an effect that reached a peak at 60 min and 
then decreased up to 24 h in a time-dependent fashion. With an increasing quantity of NF-κB mRNA, the relative quantity of 
NCAM mRNA was gradually increased upon stimulation with TNF-α up to 24 h in a time-dependent manner. D, NF-κB siRNA 
greatly reduced NCAM mRNA expression in HSG cells, in comparison with transfection using NF-κB scrambled siRNA. Each 
column and bar represents the mean ± S.E.M. of three independent experiments.BMC Cancer 2008, 8:376 http://www.biomedcentral.com/1471-2407/8/376
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Effect of cimetidine on TNF-α-mediated NF-κB activation in HSG cells Figure 3
Effect of cimetidine on TNF-α-mediated NF-κB activation in HSG cells.A, RelA protein was localized mainly in the 
cytoplasm of HSG cells and transported to the nucleus upon stimulation by TNF-α; it reached a peak at 30 min and then 
decreased at 60 min. B, the intensity of RelA expression in the HSG cell membrane was decreased by treatment with cimeti-
dine in a time-dependent manner, whereas the intensity of RelA in the cytoplasm after treatment with 10-4 M cimetidine grad-
ually increased up to 60 min. C, RelA transport was detected in the nucleus of HSG cells stimulated with 10 ng/ml of TNF-α 
and 10-4 M cimetidine for 30 min. In comparison with treatment with TNF-α alone, however, the intensity of RelA expression 
was markedly inhibited. D, left, maximum κB-dependent transcription was observed with 10 ng/ml of TNF-α at 4 h, which 
induced a 5-fold increase in luciferase activity compared with cells not exposed to TNF-α, and did not further increase with 
time. However, luciferase activities in HSG cells were time-dependently decreased in response to 10-4 M cimetidine from 4 h 
after cimetidine treatment. Half-maximal inhibition of luciferase activity was detected at 24 h after stimulation with 10-4 M 
cimetidine. Induction of luciferase activity by TNF-α was inhibited by cimetidine in a time-dependent fashion. D, right, the 
increase or decrease in luciferase activity was completely dependent on the presence of κB sites, since the control plasmid 
lacking the κB elements did not respond to TNF-α or cimetidine. Relative luciferase activities are shown as -fold induction 
compared with the activity of cimetidine-treated samples at 24 h (D, left) or untreated (D, right) samples. Each column and bar 
represents the mean ± S.E.M. of three independent experiments.BMC Cancer 2008, 8:376 http://www.biomedcentral.com/1471-2407/8/376
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mediated by three very different effects: a direct inhibitory
effect on tumor growth by blocking the cell growth-pro-
moting activity of histamine via activation of H2 recep-
tors, and an indirect effect involving inhibition of tumor-
associated angiogenesis; an immunomodulatory effect
through enhancement of the host's immune response to
tumor cells; and an inhibitory effect on cancer cell migra-
tion and adhesion to endothelial cells, thus inhibiting
tumor neo-angiogenesis and metastasis [29]. In this study,
we investigated the NCAM-associated effect of cimetidine
on tumor growth and perineural/neural invasion in sali-
vary gland tumors using an in vitro cell culture system and
an in vivo nude mice cancer model. These experiments
clearly demonstrated that cimetidine effectively down-
regulates the induction of NCAM by inhibiting the trans-
activation of NF-κB, subsequently blocks HSG adhesion
to neural cells, and ultimately induces apoptosis in HSG
cells and prevents the growth of HSG tumor masses in
nude mice.
NCAM is a membrane glycoprotein receptor of the immu-
noglobulin supergene family that mediates cell-to-cell
adhesion via homophilic binding to other NCAM mole-
cules and cell-to-substrate adhesion via heterophilic bind-
ing (NCAM binding to another ligand or counter-
receptor) [30]. NCAM plays an important role in
perineural invasion in various neoplasms, such as bile
duct cancer, gallbladder carcinoma, melanoma and ade-
noid cystic carcinoma of the head and neck [13-15,31-
33]. In a previous study [16], we reported that adenoid
cystic carcinoma is positive for NCAM and that adhesion
of the tumor cell line HSG to neural cells depends on
NCAM expression on the cell surface of both HSG and
neural cells. In addition, our previous study [12] showed
that the levels of NCAM mRNA and protein in HSG cells
were decreased by cimetidine in a dose-dependent man-
ner. Furthermore, cimetidine induced significant apopto-
sis in HSG cells by activation of caspases via the DNA-
damage signal mediated through mitochondria. As men-
tioned above, several of the actions of cimetidine, such as
the direct growth-inhibitory effects on certain cancer cell
lines [1,10] and direct stimulatory effects on lymphocyte
function [5-7] were unexpected. Some studies have also
indicated that cimetidine may have antioxidant activity
[34-36], and antioxidants have been shown to block the
NF-κB activation cascade [37]. In addition, it has also
been reported that NCAM expression is regulated by NF-
κB [18], that NF-κB activity is induced by NCAM [19], and
that NF-κB activates the expression of a number of genes
at the transcription level [21,25,26]. In other words, these
observations imply that homophilic NCAM binding can
increase NF-κB activity and that NF-κB regulates NCAM
expression.
In this study, the results of real-time quantitative RT-PCR
indicated that the activated NF-κB induced NCAM expres-
sion, and the NCAM knockdown analysis suggested that
NCAM regulates NF-κB activation induced by TNF-α in
HSG cells. It has already been reported that TNF-α induces
NF-κB activation via a common pathway based on the
phosphorylation-induced degradation of IκBs [25]. In the
present study, TNF-α was also used to activate NF-κB in
HSG cells to mimic the local inflammatory response in
the metastasized region, and some tumor cells were
reported to produce TNF-α [25]. We found that NF-κB
NCAM siRNA-mediated interference Figure 4
NCAM siRNA-mediated interference. A, endogenous 
NCAM protein was markedly reduced by NCAM siRNA. B, 
NCAM siRNA greatly reduced activation of NF-κB by TNF-α 
in HSG cells, in comparison with NCAM scrambled siRNA 
transfection. NCAM siRNA had no effect on constitutive NF-
κB activity in HSG cells. The relative luciferase activities are 
shown as -fold induction compared with the activity of 
untreated samples. Each column and bar represents the 
mean ± S.E.M. of three independent experiments.BMC Cancer 2008, 8:376 http://www.biomedcentral.com/1471-2407/8/376
Page 11 of 13
(page number not for citation purposes)
Figure 5 (see legend on next page)BMC Cancer 2008, 8:376 http://www.biomedcentral.com/1471-2407/8/376
Page 12 of 13
(page number not for citation purposes)
activation in response to TNF-α was blocked by cimeti-
dine, suggesting that cimetidine interferes with an early
common signal in the TNF-α signal transduction cascade.
Cimetidine treatment also inhibited translocation of NF-
κB into the nucleus. Thus two separate of lines of evidence
allow us to conclude that cimetidine is a potent and spe-
cific inhibitor of NF-κB activation in HSG cells: (a) cime-
tidine inhibited TNF-α-induced nuclear transactivation of
NF-κB, and (b) cimetidine suppressed NF-κB-dependent
transcription. Indeed, NF-κB controls genes that code for
anti-apoptotic proteins, some acting at the mitochondrial
level [21] or directly blocking caspase activation [38].
Down-regulation of NF-κB could therefore result in a
decrease in crucial anti-apoptotic influences both at the
mitochondrial and the membrane death receptors levels.
Most strikingly, these actions are unique to cimetidine
and are not shared by the other H2R antagonists tested.
This report, therefore, clearly demonstrates that cimeti-
dine inhibits NF-κB activation, with subsequent down-
regulation of the expression of NCAM, and that as a con-
sequence HSG cell proliferation, which requires
homophilic NCAM binding, is blocked.
We believe that this series of events provides the mecha-
nism by which cimetidine suppresses the development of
salivary gland tumors. Our data also suggest that the anti-
tumor activity of cimetidine may rely on inhibition of the
transcription factor NF-κB. However, the reason that
cimetidine, but not other H2R antagonists, interferes with
NF-κB activation remains to be elucidated.
Conclusion
We investigated the NCAM-associated effect of cimetidine
on tumor growth and perineural/neural invasion in sali-
vary gland tumors using an in vitro cell culture system and
an in vivo nude mice cancer model. These experiments
clearly demonstrated that cimetidine effectively down-
regulates the induction of NCAM by inhibiting the trans-
activation of NF-κB, which subsequently blocks HSG
adhesion to neural cells, and ultimately induces apoptosis
in HSG cells and prevents the growth of HSG tumor
masses in nude mice. These findings may explain clinical
observations by several authors [2,3] that cimetidine
improves the survival of patients with malignant tumors.
Although malignant glandular tumors are known to be
generally resistant to radiation therapy and chemother-
apy, the clinical application of cimetidine as an anti-can-
cer drug might form an integral part of future therapeutic
strategies against NCAM-expressing tumors such as ade-
noid cystic carcinoma. Further studies will be required to
identify the signal transduction pathways by which treat-
ment with cimetidine suppresses the growth of glandular
tumors and to establish a strategy for cimetidine-based
therapy of salivary gland tumors. Although malignant
glandular tumors are known to be generally resistant to
radiation therapy and chemotherapy, the clinical applica-
tion of cimetidine as an anti-cancer drug might form an
integral part of future therapeutic strategies against
NCAM-expressing tumors such as adenoid cystic carci-
noma. Further studies will be required to identify the sig-
nal transduction pathways by which cimetidine
suppresses the growth of glandular tumors and to estab-
lish a strategy for cimetidine-based therapy of salivary
gland tumors.
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